177 related articles for article (PubMed ID: 36720391)
1. Nitrosated Active Pharmaceutical Ingredients - Lessons Learned?
Holzgrabe U
J Pharm Sci; 2023 May; 112(5):1210-1215. PubMed ID: 36720391
[TBL] [Abstract][Full Text] [Related]
2. A Nitrite Excipient Database: A Useful Tool to Support N-Nitrosamine Risk Assessments for Drug Products.
Boetzel R; Schlingemann J; Hickert S; Korn C; Kocks G; Luck B; Blom G; Harrison M; François M; Allain L; Wu Y; Bousraf Y
J Pharm Sci; 2023 Jun; 112(6):1615-1624. PubMed ID: 35500671
[TBL] [Abstract][Full Text] [Related]
3. The Landscape of Potential Small and Drug Substance Related Nitrosamines in Pharmaceuticals.
Schlingemann J; Burns MJ; Ponting DJ; Martins Avila C; Romero NE; Jaywant MA; Smith GF; Ashworth IW; Simon S; Saal C; Wilk A
J Pharm Sci; 2023 May; 112(5):1287-1304. PubMed ID: 36402198
[TBL] [Abstract][Full Text] [Related]
4. Nitroso Impurities in Drug Products: An Overview of Risk Assessment, Regulatory Milieu, and Control Strategy.
Charoo NA; Dharani S; Khan MA; Rahman Z
AAPS PharmSciTech; 2023 Feb; 24(2):60. PubMed ID: 36759424
[TBL] [Abstract][Full Text] [Related]
5. Nitrosamine Impurities in Pharmaceuticals: An Empirical Review of their Detection, Mechanisms, and Regulatory Approaches.
Bhirud D; Agrawal G; Shah H; Patel A; Palkar MB; Bhattacharya S; Prajapati BG
Curr Top Med Chem; 2024; 24(6):503-522. PubMed ID: 38321910
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive review of sources of nitrosamine contamination of pharmaceutical substances and products.
Akkaraju H; Tatia R; Mane SS; Khade AB; Dengale SJ
Regul Toxicol Pharmacol; 2023 Mar; 139():105355. PubMed ID: 36792049
[TBL] [Abstract][Full Text] [Related]
7. N-Nitrosamine Formation in Pharmaceutical Solid Drug Products: Experimental Observations.
Moser J; Ashworth IW; Harris L; Hillier MC; Nanda KK; Scrivens G
J Pharm Sci; 2023 May; 112(5):1255-1267. PubMed ID: 36736774
[TBL] [Abstract][Full Text] [Related]
8. Bumetanide as a Model NDSRI Substrate: N-nitrosobumetanide Impurity Formation and its Inhibition in Bumetanide Tablets.
Shakleya D; Asmelash B; Alayoubi A; Abrigo N; Mohammad A; Wang J; Zhang J; Yang J; Marzan TA; Li D; Shaklah M; Alsharif FM; Desai S; Faustino PJ; Ashraf M; O'Connor T; Vera M; Raw A; Sayeed VA; Keire D
J Pharm Sci; 2023 Dec; 112(12):3075-3087. PubMed ID: 37364772
[TBL] [Abstract][Full Text] [Related]
9. Modified NAP test: A simple and Responsive Nitrosating Methodology for Risk Evaluation of NDSRIs.
Sharma N; Patel R; Bothara T; Jain S; Shah RP
J Pharm Sci; 2023 May; 112(5):1333-1340. PubMed ID: 36871894
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of N-Nitrosamine Formation in Drug Products: A Model Study.
Nanda KK; Tignor S; Clancy J; Marota MJ; Allain LR; D'Addio SM
J Pharm Sci; 2021 Dec; 110(12):3773-3775. PubMed ID: 34400183
[TBL] [Abstract][Full Text] [Related]
11. Modeling the Impact of Excipients Selection on Nitrosamine Formation towards Risk Mitigation.
Berardi A; Jaspers M; Dickhoff BHJ
Pharmaceutics; 2023 Jul; 15(8):. PubMed ID: 37631229
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a Novel LC-MS/MS Based Analytical Method for the Risk Assessment of Nitrosamines in Pharmaceutical Products and Packaging Materials.
Kartop RA; Güleli M; Faruzlu FA; Çalışkan C
J Pharm Sci; 2024 Jun; 113(6):1597-1606. PubMed ID: 38253223
[TBL] [Abstract][Full Text] [Related]
13. Practical and Science-Based Strategy for Establishing Acceptable Intakes for Drug Product
Dobo KL; Kenyon MO; Dirat O; Engel M; Fleetwood A; Martin M; Mattano S; Musso A; McWilliams JC; Papanikolaou A; Parris P; Whritenour J; Yu S; Kalgutkar AS
Chem Res Toxicol; 2022 Mar; 35(3):475-489. PubMed ID: 35212515
[TBL] [Abstract][Full Text] [Related]
14. Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA).
Kruhlak NL; Schmidt M; Froetschl R; Graber S; Haas B; Horne I; Horne S; King ST; Koval IA; Kumaran G; Langenkamp A; McGovern TJ; Peryea T; Sanh A; Siqueira Ferreira A; van Aerts L; Vespa A; Whomsley R
Regul Toxicol Pharmacol; 2024 Jun; 150():105640. PubMed ID: 38754805
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of nitrosamine contaminants in drug samples: Has the crisis been overcome?
Schmidtsdorff S; Neumann J; Schmidt AH; Parr MK
Arch Pharm (Weinheim); 2023 Feb; 356(2):e2200484. PubMed ID: 36461687
[TBL] [Abstract][Full Text] [Related]
16. An Elemental Impurities Excipient Database: A Viable Tool for ICH Q3D Drug Product Risk Assessment.
Boetzel R; Ceszlak A; Day C; Drumm P; Gil Bejar J; Glennon J; Harris L; Heghes CI; Horga R; Jacobs PL; Keurentjes WJTM; King F; Lee CW; Lewen N; Marchant CA; Maris FA; Nye W; Powell S; Rockstroh H; Rutter L; Schweitzer M; Shannon E; Smallshaw L; Teasdale A; Thompson S; Wilkinson D
J Pharm Sci; 2018 Sep; 107(9):2335-2340. PubMed ID: 29679706
[TBL] [Abstract][Full Text] [Related]
17. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals.
Wichitnithad W; Nantaphol S; Noppakhunsomboon K; Rojsitthisak P
Saudi Pharm J; 2023 Feb; 31(2):295-311. PubMed ID: 36942272
[TBL] [Abstract][Full Text] [Related]
18. N-nitrosamine Mitigation with Nitrite Scavengers in Oral Pharmaceutical Drug Products.
Bayne AV; Misic Z; Stemmler RT; Wittner M; Frerichs M; Bird JK; Besheer A
J Pharm Sci; 2023 Jul; 112(7):1794-1800. PubMed ID: 37023856
[TBL] [Abstract][Full Text] [Related]
19. Nitrosamines crisis in pharmaceuticals - Insights on toxicological implications, root causes and risk assessment: A systematic review.
Vikram HPR; Kumar TP; Kumar G; Beeraka NM; Deka R; Suhail SM; Jat S; Bannimath N; Padmanabhan G; Chandan RS; Kumar P; Gurupadayya B
J Pharm Anal; 2024 May; 14(5):100919. PubMed ID: 38799236
[TBL] [Abstract][Full Text] [Related]
20. Regulatory Experiences with Root Causes and Risk Factors for Nitrosamine Impurities in Pharmaceuticals.
Horne S; Vera MD; Nagavelli LR; Sayeed VA; Heckman L; Johnson D; Berger D; Yip YY; Krahn CL; Sizukusa LO; Rocha NFM; Bream RN; Ludwig J; Keire DA; Condran G
J Pharm Sci; 2023 May; 112(5):1166-1182. PubMed ID: 36599405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]